Neurovation Labs, Inc. Secures Seed Funding for Post-traumatic Stress Disorder Diagnostic

NEW YORK, Jun. 21, 2022 /PRNewswire/- Neurovation Labs, Inc., a biotechnology company developing Post-traumatic Stress Disorder (“PTSD”) diagnostics and treatments, is pleased to announce that it has successfully raised its seed funding round earlier this month. This financing was completed with the support of individual angel investors based in the United States.

Neurovation Labs intends to use the proceeds to further the development of its patent-pending PTSD diagnostic. It will commence the next set of pre-clinical studies next month, testing the efficacy of using radiological imaging technology to diagnose PTSD.

Neurovation Labs was founded based on the research performed by Dr. Jennifer Perusini, CEO, and Dr. Michael Fanselow, Director of Research that sought to understand the cause of PTSD on a physiological level. They discovered an objective indicator of PTSD – an enduring protein increase within the part of the brain central to fear learning – potentially the first biomarker for detecting the disease. Moreover, early research showed that stabilizing the protein levels could reverse PTSD. Neurovation Labs now aims to leverage these discoveries to develop detection methods and ultimately a cure for the disorder.

About Neurovation Labs

Neurovation Labs is an early stage biotechnology company focused on diagnosing and treating anxiety disorders and in particular PTSD. PTSD is an incapacitating disorder that currently has no objective diagnostic and ineffective treatment options. Based in New York, NY and founded in 2016, Neurovation Labs is poised to expand upon its groundbreaking research to address this unmet medical need.

For this press release and more information about Neurovation Labs, please visit www.neurovationlabs.com.